Clinical Trial Update: A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) [Phase 1]

View source ↗

Summary

First-in-human, dose-escalation Phase 1 study of a dendritic cell vaccine (DCV) is underway, with recruitment for leptomeningeal carcinomatosis and certain brea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Leptomeningeal Carcinomatosis
• Triple-negative Breast Cancer

Drugs mentioned

• Dendritic Cell Vaccine (DCV) (dendritic cell vaccine)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Leptomeningeal Disease, Triple Negative Breast Cancer | Phase 1 | Status: RECRUITING